On Apr. 16, 2020, BioSig Technologies announced that its subsidiary ViralClear Pharmaceuticals, had updated its clinical development program for Vicromaxﾙ (merimepodib, or MMPD) as a treatment for COVID-19. Under the terms of a new agreement, the Phase II clinical trial wasconducted at Mayo Clinic. The study was a randomized, placebo-controlled trial. Data from the Phase II trial was expected within three months.

The study will be a randomized, placebo-controlled trial. Data from the Phase II trial is expected within three months. “This trial is a part of our commitment to accelerate discoveries related to the SARS-CoV-2 virus and the disease it causes, COVID-19,” says Andrew D. Badley, M.D., infectious disease expert, chair of the COVID-19 Research Task Force at Mayo Clinic.

Anti-viral candidate merimepodib (MMPD) targets RNA-dependent polymerases. The molecule has shown activity against a broad spectrum of RNA viruses and has demonstrated satisfactory safety data from over 300 patients treated for hepatitis C. Recently, the Company published first pre-clinical data generated under contract with Galveston National Laboratory at The University of Texas Medical Branch.